KRYS
Krystal Biotech, Inc.
$317.97
-1.11%
$9.4B
No data for this timeframe.
Vol
Market Cap$9.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders50 funds
Inst. Value$5.5B
Inst. Activity21 buys / 9 sells
Insider Activity0B / 11S
Insider Net $-$7.7M
SEC Reports8
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001711279·Prev Close $321.55
Recent Activity
Jun 5, 2026
SEC
President and CEO Krishnan Krish S and President of R&D Krishnan Suma each sold 320 shares of Krystal Biotech on June 4,
CLUSTER — Impact 2/10
Jun 4, 2026
Insider
Krishnan Suma sold 320 shares
President, R&D @ $300.75 ($96.2K)
Jun 4, 2026
Insider
Krishnan Krish S sold 320 shares
President and CEO @ $300.75 ($96.2K)
May 26, 2026
Insider
Thomas John Charles sold 642 shares
EVP, General Counsel @ $302.03 ($193.9K)
May 16, 2026
SEC
Citigroup upgrades KRYS to Buy — PT $309 (+56% from prior); stock at $312.58, near consensus mean
ANALYST-UPGRADE — Impact 5/10
Apr 16, 2026
SEC
Citigroup upgrades KRYS to Buy — PT $309 (+18%)
ANALYST-UPGRADE — Impact 4/10
Inst.
FIRST TRUST ADVISORS LP — ADD
350,521 shares ($90.5M)
Inst.
BANK OF AMERICA CORP — ADD
260,647 shares ($67.3M)
Price Targets
$322.78
+1.5% upside
Hold
Current $317.97
Low $241.00
Median $310.00
High $399.00
9 analysts
$241.00
$399.00
Analyst Ratings
7Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 5, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.94 ▲ +15.2% | $1.28 — $3.64 | 51% YoY | 9 |
| Next Q | $2.19 ▲ +10.3% | $1.42 — $4.12 | -18% YoY | 9 |
| Current FY | $8.38 ▲ +10.6% | $6.21 — $14.52 | 22% YoY | 10 |
| Next FY | $10.08 ▼ -1.1% | $6.66 — $13.42 | 20% YoY | 10 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $1.1B | — |
| BlackRock, Inc. | $1.0B | — |
| Avoro Capital Advisors LLC | $746.3M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $376.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Krishnan Suma | SELL | $96.2K |
| Jun 4, 2026 | Krishnan Krish | SELL | $96.2K |
| May 26, 2026 | Thomas John | SELL | $193.9K |
| Mar 4, 2026 | Krishnan Krish | SELL | $124.3K |
| Mar 4, 2026 | Krishnan Suma | SELL | $104.7K |
50 institutional holders with $5.5B total value (21,332,244 shares) as of 2026-Q1. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 21 institutions added/increased vs 9 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 4,373,987 | $1.1B | 20.5% | — |
| 3 | BlackRock, Inc. | 3,940,456 | $1.0B | 18.5% | — |
| 4 | Avoro Capital Advisors LLC | 2,888,888 | $746.3M | 13.5% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,456,727 | $376.3M | 6.8% | — |
| 6 | STATE STREET CORP | 1,314,434 | $339.5M | 6.2% | — |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,165,324 | $301.0M | 5.5% | — |
| 8 | Capital World Investors | 824,720 | $213.0M | 3.9% | — |
| 9 | Hood River Capital Management LLC | 619,586 | $160.1M | 2.9% | — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 468,990 | $121.1M | 2.2% | — |
| 11 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 407,178 | $105.2M | 1.9% | DOUBLED +152.1% |
| 12 | FIRST TRUST ADVISORS LP | 350,521 | $90.5M | 1.6% | ADD +42.9% |
| 13 | JANUS HENDERSON GROUP PLC | 266,659 | $68.9M | 1.3% | DOUBLED +2078.9% |
| 14 | BANK OF AMERICA CORP /DE/ | 260,647 | $67.3M | 1.2% | ADD +36.6% |
| 15 | Invesco Ltd. | 251,373 | $64.9M | 1.2% | DOUBLED +318.9% |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 241,986 | $62.5M | 1.1% | — |
| 17 | GOLDMAN SACHS GROUP INC | 214,949 | $55.5M | 1.0% | — |
| 18 | MORGAN STANLEY | 209,082 | $54.0M | 1.0% | — |
| 19 | FRANKLIN RESOURCES INC | 179,265 | $46.3M | 0.8% | ADD +42.6% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 179,161 | $46.3M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FIRST TRUST ADVISORS LP | ADD | 245,276 | 350,521 | +42.9% | $90.5M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 190,807 | 260,647 | +36.6% | $67.3M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 60,008 | 251,373 | +318.9% | $64.9M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 125,675 | 179,265 | +42.6% | $46.3M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 156,568 | 110,665 | -29.3% | $28.6M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 183,754 | 68,343 | -62.8% | $17.7M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 32,310 | 46,570 | +44.1% | $12.0M | 2026-Q1 |
| 1832 Asset Management L.P. | DOUBLED | 17,600 | 42,600 | +142.0% | $11.0M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 26,461 | 40,715 | +53.9% | $10.5M | 2026-Q1 |
| Neuberger Berman Group LLC | DOUBLED | 1,033 | 33,084 | +3102.7% | $8.5M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 14,466 | 20,691 | +43.0% | $5.3M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 24,268 | 17,687 | -27.1% | $4.6M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 1,375 | 14,476 | +952.8% | $3.7M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 3,300 | 9,600 | +190.9% | $2.5M | 2026-Q1 |
| Erste Asset Management GmbH | ADD | 5,700 | 8,700 | +52.6% | $2.1M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 146 | 5,925 | +3958.2% | $1.5M | 2026-Q1 |
| Amundi | ADD | 3,754 | 5,706 | +52.0% | $1.5M | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | ADD | 2,231 | 3,162 | +41.7% | $816.8K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 2,127 | 3,027 | +42.3% | $781.9K | 2026-Q1 |
| Swiss Life Asset Management Ltd | DOUBLED | 991 | 2,165 | +118.5% | $559.3K | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 1,112 | 2,049 | +84.3% | $529.3K | 2026-Q1 |
| NATIXIS | TRIM | 2,920 | 1,736 | -40.5% | $448.4K | 2026-Q1 |
| Mariner, LLC | NEAR_EXIT | 4,320 | 1,048 | -75.7% | $270.5K | 2026-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | TRIM | 2,000 | 1,000 | -50.0% | $258.3K | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | TRIM | 926 | 688 | -25.7% | $177.7K | 2026-Q1 |
6 unique insiders with 28 transactions. Net insider value: -$7.7M ($0.00 bought, $7.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Krishnan Suma | President, R&D | SELL | 320 | $300.75 | $96.2K |
| Jun 4, 2026 | Krishnan Krish S | President and CEO | SELL | 320 | $300.75 | $96.2K |
| May 26, 2026 | Thomas John Charles | EVP, General Counsel | SELL | 642 | $302.03 | $193.9K |
| Mar 4, 2026 | Krishnan Krish S | President and CEO | SELL | 483 | $257.31 | $124.3K |
| Mar 4, 2026 | Krishnan Suma | President, R&D | SELL | 407 | $257.32 | $104.7K |
| Mar 2, 2026 | ROMANO KATHRYN | Chief Accounting Officer | SELL | 750 | $267.60 | $200.7K |
| Feb 27, 2026 | JANNEY DANIEL | Director | SELL | 9,430 | $275.45 | $2.6M |
| Feb 27, 2026 | Krishnan Suma | President, R&D | EXERCISE | 22,500 | — | — |
| Feb 27, 2026 | Krishnan Suma | President, R&D | EXERCISE | 4,000 | — | — |
| Feb 27, 2026 | Krishnan Suma | President, R&D | AWARD | 18,100 | — | — |
| Feb 27, 2026 | Krishnan Suma | President, R&D | AWARD | 7,256 | — | — |
| Feb 27, 2026 | Krishnan Suma | President, R&D | AWARD | 43,536 | — | — |
| Feb 27, 2026 | Krishnan Krish S | President and CEO | EXERCISE | 8,750 | — | — |
| Feb 27, 2026 | Krishnan Krish S | President and CEO | EXERCISE | 26,250 | — | — |
| Feb 27, 2026 | Krishnan Krish S | President and CEO | AWARD | 45,249 | — | — |
| Feb 27, 2026 | Krishnan Krish S | President and CEO | AWARD | 18,140 | — | — |
| Feb 27, 2026 | ROMANO KATHRYN | Chief Accounting Officer | EXERCISE | 7,500 | — | — |
| Feb 27, 2026 | ROMANO KATHRYN | Chief Accounting Officer | EXERCISE | 550 | — | — |
| Feb 27, 2026 | ROMANO KATHRYN | Chief Accounting Officer | AWARD | 13,575 | — | — |
| Feb 27, 2026 | ROMANO KATHRYN | Chief Accounting Officer | AWARD | 5,442 | — | — |
| Feb 26, 2026 | JANNEY DANIEL | Director | SELL | 5,103 | $275.28 | $1.4M |
| Feb 25, 2026 | JANNEY DANIEL | Director | SELL | 700 | $275.00 | $192.5K |
| Feb 24, 2026 | JANNEY DANIEL | Director | EXERCISE | 37,895 | $2.46 | $93.2K |
| Feb 19, 2026 | ROSSI DINO A | Director | EXERCISE | 18,950 | $8.79 | $166.6K |
| Feb 19, 2026 | ROSSI DINO A | Director | SELL | 8,116 | $260.49 | $2.1M |
| Feb 9, 2026 | ROMANO KATHRYN | Chief Accounting Officer | GIFT | 750 | — | — |
| Feb 9, 2026 | ROMANO KATHRYN | Chief Accounting Officer | SELL | 2,000 | $270.56 | $541.1K |
| Feb 9, 2026 | ROMANO KATHRYN | Chief Accounting Officer | EXERCISE | 12,500 | $63.55 | $794.4K |
8 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.8/10.
BULLISH
ANALYST-UPGRADE
5/10
Citigroup upgrades KRYS to Buy — PT $309 (+56% from prior); stock at $312.58, near consensus mean
May 16, 2026
BULLISH
ANALYST-UPGRADE
4/10
Citigroup upgrades KRYS to Buy — PT $309 (+18%)
Apr 16, 2026
NEUTRAL
CLUSTER
2/10
President and CEO Krishnan Krish S and President of R&D Krishnan Suma each sold 320 shares of Krysta
Jun 5, 2026
BULLISH
PRESS-RELEASE
6/10
Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and dilut
May 4, 2026
NEUTRAL
PRESS-RELEASE
3/10
Krystal Biotech announced it will report Q1 2026 financial results on May 4, 2026. No financial resu
Apr 21, 2026
NEUTRAL
DEFA14A
2/10
Krystal Biotech filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meeting. Th
Apr 3, 2026
NEUTRAL
CLUSTER
3/10
Krystal Biotech CEO Krishnan Krish and Chief Accounting Officer Kathryn Romano sold shares in the op
Mar 6, 2026
NEUTRAL
CLUSTER
5/10
Krystal Biotech insiders executed a cluster of trades over the past week, including open-market sale
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 18 analysts: 7 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$322.78 mean target
+1.5% upside
Hold (1.18)
$241.00 Low
$399.00 High
| Metric | Value |
|---|---|
| Current Price | $317.97 |
| Target Low | $241.00 |
| Target Mean | $322.78 |
| Target Median | $310.00 |
| Target High | $399.00 |
| # Analysts | 9 |
| Recommendation | Hold (1.18) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.94 | $1.28 | $3.64 | 50.5% | +15.2% | 1↑ 2↓ | $0.1B | 30.4% | 9 |
| Next Q 2026-09-30 |
$2.19 | $1.42 | $4.12 | -17.8% | +10.3% | 1↑ 3↓ | $0.1B | 40.4% | 9 |
| Current FY 2026-12-31 |
$8.38 | $6.21 | $14.52 | 22.5% | +10.6% | 3↑ 2↓ | $0.5B | 35.9% | 10 |
| Next FY 2027-12-31 |
$10.08 | $6.66 | $13.42 | 20.3% | -1.1% | 4↑ 2↓ | $0.7B | 28.1% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.942 | |
| 7d ago | $1.942 | |
| 30d ago | $1.685 | +0.257 |
| 60d ago | $1.747 | +0.195 |
| 90d ago | $1.705 | +0.237 |
10 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 5, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 27, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| Feb 25, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 6, 2026 | Citigroup | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 10 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
May 4, 2026
earnings
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
<p align="center">$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch</p>
May 4, 2026
earnings_calendar
KRYS Q1 2026 Earnings Before Market Open — 2026-05-04
Apr 30, 2026
other
Krystal Biotech to Present at Upcoming Scientific Conferences
<p>PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.krystalbio.com/" rel="nofollow" target="_blank" title=""><u>Krystal Biotech,
Apr 21, 2026
earnings
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
<p>PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.krystalbio.com/" rel="nofollow" target="_blank" title=""><u>Krystal Biotech,
Apr 21, 2026
short_interest
FTD: KRYS — 6,493 shares ($1.8M) failed to deliver
Settlement: 20260421, Price: $276.50, FTD Value: $1,795,314.5, KRYSTAL BIOTECH INC COM (USA)
Mar 9, 2026
short_interest
FTD: KRYS — 2,097 shares ($0.5M) failed to deliver
Settlement: 20260309, Price: $253.69, FTD Value: $531,987.93, KRYSTAL BIOTECH INC COM (USA)
Feb 19, 2026
short_interest
FTD: KRYS — 24,545 shares ($7.0M) failed to deliver
Settlement: 20260219, Price: $283.29, FTD Value: $6,953,353.05, KRYSTAL BIOTECH INC COM (USA)
Feb 9, 2026
short_interest
FTD: KRYS — 2,032 shares ($0.6M) failed to deliver
Settlement: 20260209, Price: $272.74, FTD Value: $554,207.68, KRYSTAL BIOTECH INC COM (USA)